Leerink Partners Initiates Coverage On Larimar Therapeutics With Outperform Rating, Announces Price Target of $25

Moomoo 24/7 ·  Apr 3 09:18

Leerink Partners analyst Joori Park initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Outperform rating and announces Price Target of $25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment